Micelle-like nanoparticles as carriers for DNA and siRNA
- PMID: 25557580
- PMCID: PMC4492123
- DOI: 10.1021/mp5007213
Micelle-like nanoparticles as carriers for DNA and siRNA
Abstract
Gene therapy represents a potential efficient approach of disease prevention and therapy. However, due to their poor in vivo stability, gene molecules need to be associated with delivery systems to overcome extracellular and intracellular barriers and allow access to the site of action. Cationic polymeric nanoparticles are popular carriers for small interfering RNA (siRNA) and DNA-based therapeutics for which efficient and safe delivery are important factors that need to be optimized. Micelle-like nanoparticles (MNP) (half micelles, half polymeric nanoparticles) can overcome some of the disadvantages of such cationic carriers by unifying in one single carrier the best of both delivery systems. In this review, we will discuss how the unique properties of MNP including self-assembly, condensation and protection of nucleic acids, improved cell association and gene transfection, and low toxicity may contribute to the successful application of siRNA- and DNA-based therapeutics into the clinic. Recent developments of MNP involving the addition of stimulus-sensitive functions to respond specifically to pathological or externally applied "triggers" (e.g., temperature, pH or enzymatic catalysis, light, or magnetic fields) will be discussed. Finally, we will overview the use of MNP as two-in-one carriers for the simultaneous delivery of different agents (small molecules, imaging agents) and nucleic acid combinations.
Keywords: DNA delivery; cationic amphiphiles; cationic polymers; complexes; gene delivery; micelle-like nanoparticles; siRNA delivery.
Conflict of interest statement
The authors declare no competing financial interest.
Figures


Similar articles
-
Stimulus-sensitive polymeric nanoparticles and their applications as drug and gene carriers.Adv Healthc Mater. 2013 Mar;2(3):388-417. doi: 10.1002/adhm.201200313. Epub 2012 Nov 2. Adv Healthc Mater. 2013. PMID: 23184586 Review.
-
Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.Biomaterials. 2013 Nov;34(33):8408-15. doi: 10.1016/j.biomaterials.2013.07.019. Epub 2013 Aug 7. Biomaterials. 2013. PMID: 23932248
-
Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery.Biomaterials. 2008 Nov;29(32):4348-55. doi: 10.1016/j.biomaterials.2008.07.036. Epub 2008 Aug 19. Biomaterials. 2008. PMID: 18715636
-
Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.Mol Pharm. 2012 Oct 1;9(10):2863-74. doi: 10.1021/mp300193f. Epub 2012 Sep 4. Mol Pharm. 2012. PMID: 22924580
-
Sugar-based amphiphilic polymers for biomedical applications: from nanocarriers to therapeutics.Acc Chem Res. 2014 Oct 21;47(10):2867-77. doi: 10.1021/ar4003009. Epub 2014 Aug 20. Acc Chem Res. 2014. PMID: 25141069 Review.
Cited by
-
Progress and challenges of plant-derived nucleic acids as therapeutics in macrophage-mediated RNA therapy.Front Immunol. 2023 Dec 8;14:1255668. doi: 10.3389/fimmu.2023.1255668. eCollection 2023. Front Immunol. 2023. PMID: 38155963 Free PMC article. Review.
-
Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue.Small. 2016 Sep;12(35):4837-4848. doi: 10.1002/smll.201600925. Epub 2016 Jul 19. Small. 2016. PMID: 27432595 Free PMC article.
-
PnBA-b-PNIPAM-b-PDMAEA Thermo-Responsive Triblock Terpolymers and Their Quaternized Analogs as Gene and Drug Delivery Vectors.Polymers (Basel). 2021 Jul 19;13(14):2361. doi: 10.3390/polym13142361. Polymers (Basel). 2021. PMID: 34301119 Free PMC article.
-
Combined Photosensitive Gene Therapy Effective Against Triple-Negative Breast Cancer in Mice Model.Int J Nanomedicine. 2024 Feb 23;19:1809-1825. doi: 10.2147/IJN.S449042. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38414523 Free PMC article.
-
Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence.AAPS J. 2019 Apr 23;21(4):57. doi: 10.1208/s12248-019-0325-y. AAPS J. 2019. PMID: 31016543 Review.
References
-
- Anderson WF, Blaese RM, Culver K. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther. 1990;1(3):331–62. - PubMed
-
- Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15(2):65–77. - PubMed
-
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources